# US 2022/0010016 A1 · Treatment of metastatic pancreatic adenocarcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010016 A1
- Document ID: US20220010016A1
- Status: Published application
- Kind: A1
- Application number: 17/285,511
- Filed: 2019-10-17
- Published: 2022-01-13
- Earliest claimed: 2018-10-17
- Assignees: BioLineRx Ltd.; Merck Sharp & Dohme Corp.
- Applicants: BioLineRx Ltd.; Merck Sharp & Dohme Corp.
- Inventors: Abi VAINSTEIN-HARAS; Ella SORANI; Irit GLIKO-KABIR; Osnat BOHANA-KASHTAN; Amnon PELED
- Web page: https://patentgrep.com/patent/US20220010016A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 16/2818: {against CD28 or CD152}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.

## Claims

### Claim 1

A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein said anti PD-1 is pembrolizumab.

### Claim 5 (depends on 1)

The method of claim 1, wherein said chemotherapy comprises a plurality of chemotherapeutic agents.

### Claim 6 (depends on 1)

The method of claim 1, wherein said chemotherapy comprises irinotecan, fluorouracil (5-FU) and leucovorin (LV).

### Claim 7 (depends on 1)

The method of claim 1, wherein said irinotecan is liposome-encapsulated.

### Claim 8 (depends on 1)

The method of claim 1, wherein said irinotecan is Onivyde®.

### Claim 9 (depends on 1)

The method of claim 1, wherein said peptide is administered subcutaneously (SC).

### Claim 10 (depends on 1)

The method of claim 1, wherein said peptide is administered at a dose of 1.25 mg/kg.

### Claim 11 (depends on 1)

The method of claim 1, wherein said anti PD-1 is administered intravenously (IV).

### Claim 12 (depends on 1)

The method of claim 1, wherein said anti PD-1 is administered at a dose of 200 mg.

### Claim 13 (depends on 1)

The method of claim 1, wherein said chemotherapy is administered intravenously.

### Claim 14 (depends on 1)

The method of claim 1, wherein said treatment comprises a monotherapy period with said peptide followed by a combination therapy with said peptide, said anti PD-1 and said chemotherapy.

### Claim 15 (depends on 1)

The method of claim 1, wherein said combination therapy with said chemotherapy and said anti PD-1 is initiated on Day 8.

### Claim 16 (depends on 14)

The method of claim 14, wherein said combination therapy is repeated every 2 weeks with said chemotherapy and every 3 weeks with said anti PD-1.

### Claim 17 (depends on 15)

The method of claim 15, wherein said combination therapy with said peptide is initiated on Day 10 two times a week on non-consecutive days, 48 hours apart.

### Claim 18 (depends on 1)

The method of claim 1, wherein said monotherapy is and performed on Days 1-5, daily.

### Claim 19 (depends on 18)

The method of claim 18, wherein said treatment further comprises an anti-histamine and optionally analgesics.

### Claim 20 (depends on 1)

The method of claim 1, wherein said combination therapy continues for up to 35 treatments.

### Claim 21 (depends on 1)

The method of claim 1, wherein said subject is post first-line treatment against said metastatic pancreatic adenocarcinoma or wherein said first-line treatment comprises a gemcitabine-based chemotherapy.

### Claim at position 21

22-25. (canceled)
